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Abstract
Introduction:  Major  bleeding  is  a  serious  complication  of  acute  coronary  syndrome  (ACS)  and
is associated  with  a  worse  prognosis.  The  CRUSADE  bleeding  score  is  used  to  stratify  the  risk  of
major bleeding  in  ACS.
Objective:  To  assess  the  predictive  ability  of  the  CRUSADE  score  in  a  contemporary  ACS  popu-
lation.
Methods: In  a  single-center  retrospective  study  of  2818  patients  admitted  with  ACS,  the  CRU-
SADE score  was  calculated  for  each  patient  and  its  discrimination  and  goodness  of  fit  were
assessed  by  the  area  under  the  receiver  operating  characteristic  curve  (AUC)  and  by  the  Hosmer-
Lemeshow  test,  respectively.  Predictors  of  in-hospital  major  bleeding  (IHMB)  were  determined.
Results:  The  IHMB  rate  was  1.8%,  significantly  lower  than  predicted  by  the  CRUSADE  score  (7.1%,
p<0.001). The  incidence  of  IHMB  was  0.5%  in  the  very  low  risk  category  (rate  predicted  by  the
score 3.1%),  1.5%  in  the  low  risk  category  (5.5%),  1.6%  in  the  moderate  risk  category  (8.6%),
5.5% in  the  high  risk  category  (11.9%),  and  4.4%  in  the  very  high  risk  category  (19.5%).  The
predictive ability  of  the  CRUSADE  score  for  IHMB  was  only  moderate  (AUC  0.73).
The in-hospital  mortality  rate  was  4.0%.  Advanced  age  (p=0.027),  femoral  vascular  access
(p=0.004),  higher  heart  rate  (p=0.047)  and  ticagrelor  use  (p=0.027)  were  independent  predictors
of IHMB.
Conclusions:  The  CRUSADE  score,  although  presenting  some  discriminatory  power,  significantly
overestimated  the  IHMB  rate,  especially  in  patients  at  higher  risk.  These  results  question
whether the  CRUSADE  score  should  continue  to  be  used  in  the  stratification  of  ACS.
© 2018  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
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Score  CRUSADE  --  Será  ainda  um  bom  score  para  prever  a  hemorragia  na  síndrome
coronária  aguda?
Resumo
Introduc¸ão:  A  hemorragia  major  (HM)  é  uma  complicac¸ão  grave  da  síndrome  coronária  aguda
(SCA) e  está  associada  a  pior  prognóstico.  O  score  CRUSADE  permite  estratificar  o  risco  de  HM
na SCA.
Objetivo:  Avaliar  a  capacidade  preditiva  do  score  CRUSADE  numa  populac¸ão  contemporânea  de
SCA.
Métodos: Estudo  unicêntrico  e  retrospetivo  com  2.818  doentes  admitidos  por  SCA.  O  score
CRUSADE foi  calculado  para  cada  doente,  a  sua  discriminac¸ão  e  calibrac¸ão  foram  avaliadas  pela
área abaixo  da  curva  (AUC)  Receiver  Operating  Characteristic  e  pelo  teste  Hosmer-Lemeshow,
respetivamente.  Foram  determinados  os  preditores  de  HM  intra-hospitalar  (HMIH).
Resultados:  A  taxa  de  HMIH  foi  de  1.8%,  valor  significativamente  inferior  ao  estimado  pelo
score CRUSADE  (7,1%,  p<0,001).  A  incidência  de  HMIH  nas  diferentes  categorias  foi  de  0,5%  na
de muito  baixo  risco  (taxa  estimada  pelo  score  de  3,1%);  1,5%  na  de  baixo  (estimada  de  5,5%);
1,6% na  de  moderado  (estimada  de  8,6%);  5,5%  na  de  elevado  (estimada  de  11,9%)  e  4,4%  na  de
muito elevado  (estimada  de  19,5%).  A  capacidade  preditora  do  score  CRUSADE  para  HMIH  foi
apenas moderada  (AUC  0,73).  A  taxa  de  mortalidade  intra-hospitalar  foi  de  4,0%.  A  idade  mais
avanc¸ada (p=0,027),  o  acesso  vascular  femoral  (p=0,004),  a  frequência  cardíaca  mais  elevada
(p=0,047)  e  o  ticagrelor  (p=0,027)  foram  preditores  independentes  de  HMIH.
Conclusão:  O  score  CRUSADE,  apesar  de  apresentar  algum  poder  discriminatório,  sobrestimou
de forma  significativa  a  taxa  de  HMIH,  principalmente  nos  doentes  de  maior  risco.  Esses  result-
ados questionam  se  o  score  CRUSADE  deverá  continuar  a  ser  usado  na  estratificac¸ão  da  SCA.
© 2018  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este e´ um
artigo Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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ACS  acute  coronary  syndrome
AUC  area  under  the  curve
CABG  coronary  artery  bypass  grafting
CI  confidence  interval
COPD  chronic  obstructive  pulmonary  disease
GP  glycoprotein
IHMB  in-hospital  major  bleeding
LVEF  left  ventricular  ejection  fraction
MI  myocardial  infarction
OR  odds  ratio
PCI  percutaneous  coronary  intervention
ntroduction
atients  with  acute  coronary  syndrome  (ACS)  are  a  hetero-
eneous  population,  with  varying  levels  of  risk  for  events,
nd  so  initial  assessment  has  a  crucial  role  in  deciding  the
ost  appropriate  therapeutic  strategy.1 Treatment  of  these
atients  includes  antithrombotic  therapy  and  invasive  pro-
edures,  which  carry  an  increased  risk  of  bleeding,2 the
ncidence  of  which  ranges  between  1%  and  10%.3 This  vari-
bility  in  the  incidence  of  bleeding  complications  is  due  to
t
c
marious  factors,  including  differences  in  patient  character-
stics,  concomitant  treatment  and  definitions  of  bleeding.3
evertheless,  whatever  definition  is  used,  multiple  studies
ave  shown  that  bleeding  complications  are  associated  with
dverse  events  including  death,  non-fatal  myocardial  infarc-
ion  (MI),  stroke,  and  stent  thrombosis.3--5
Assessment  of  the  risk  of  bleeding  includes  a  detailed
istory  of  bleeding  symptoms,  identification  of  predisposing
omorbidities,  laboratory  data,  and  calculation  of  a  bleeding
isk  score.6
The  CRUSADE  score7 was  developed  to  assess  bleed-
ng  risk  based  on  a varied  population  of  patients  with
on-ST-elevation  ACS  (NSTE-ACS),  and  was  subsequently  val-
dated  for  ST-elevation  myocardial  infarction  (STEMI).8 It
s  calculated  from  eight  variables  that  include  baseline
haracteristics,  clinical  variables  and  admission  laboratory
alues.7 It  is  currently  the  most  commonly  used  score  to
etermine  bleeding  risk,  due  to  its  proven  discriminatory
ower.6,9,10
The  main  purpose  of  the  CRUSADE  score  is  to  strat-
fy  bleeding  risk  in  patients  with  ACS,  in  order  to  select
ppropriate  therapeutic  strategies  that  will  reduce  bleeding
vents  and  hence  improve  prognosis.9
The  aim  of  this  study  is  to  analyze  the  applicability  of
he  CRUSADE  score  in  ACS  patients,  in  light  of  the  significant
hanges  that  have  taken  place  over  the  last  decade  in  the
anagement  and  treatment  of  these  patients.
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Methods
Study  design
This  was  a  retrospective,  descriptive,  correlational  study  of
patients  admitted  with  a  diagnosis  of  ACS  to  the  cardiology
department  of  Centro  Hospitalar  Universitário  do  Algarve
between  October  1,  2010  and  August  31,  2014.  The  CRU-
SADE  score  was  calculated  for  each  patient  and  its  ability
to  predict  in-hospital  major  bleeding  (IHMB)  was  assessed.
Predictors  of  IHMB  were  determined.
Patient  selection
A  total  of  2818  patients  diagnosed  with  ACS  in  the  previous
48  hours  were  included.  MI  was  diagnosed  in  the  presence
of  chest  pain  or  anginal  equivalent  in  the  previous  48  hours
together  with  ischemic  electrocardiographic  changes  (ST-
segment  deviation  or  negative  T  waves)  and  elevation  of
troponin  levels  above  the  reference  value.  Unstable  angina
was  defined  as  the  presence  of  chest  pain  or  anginal  equiv-
alent  with  or  without  with  ischemic  electrocardiographic
changes  in  the  absence  of  elevation  of  troponin  levels  above
the  reference  value.
Patients  with  MI  associated  with  revascularization  pro-
cedures  (types  4  and  5)  or  type  2  MI  according  to
the  ESC/ACCF/AHA/WHF  universal  definition  of  myocardial
infarction11 were  excluded.
In  the  analysis  of  the  predictive  ability  of  the  CRUSADE
score,  203  of  the  2818  patients  (7.2%)  were  excluded  due  to
inability  to  calculate  the  score.
Data  collection
Data  were  collected  on  demographics  (age  and  gender),
relevant  personal  history  (MI,  heart  failure,  percutaneous
coronary  intervention  [PCI],  coronary  artery  bypass  graft
surgery,  chronic  obstructive  pulmonary  disease  [COPD]  and
cancer),  and  cardiovascular  risk  factors  (hypertension,  dia-
betes,  dyslipidemia  and  smoking  status).  Data  were  also
analyzed  on  hospital  stay,  including  clinical  parameters  at
admission  (systolic  blood  pressure,  heart  rate  and  hemat-
ocrit),  coronary  angiography  (vascular  access  and  PCI),  left
ventricular  ejection  fraction  (LVEF),  type  of  ACS  (STEMI,
non-ST-segment  MI  [NSTEMI],  MI  of  undetermined  location,
or  unstable  angina),  and  medication  (aspirin,  clopidogrel,
ticagrelor,  enoxaparin,  unfractionated  heparin,  warfarin,
and  glycoprotein  [GP]  IIb/IIIa  inhibitors).
Creatinine  clearance  was  estimated  by  the  Cockcroft-
Gault  formula.12
Vascular  disease  was  identified  on  the  basis  of  a  history
of  peripheral  arterial  disease  and/or  stroke.
In-hospital  mortality  was  defined  as  death  from  any  cause
during  hospitalization  for  ACS.Study  objectives
The  study  objectives  were  assessment  of  the  predictive
ability  of  the  CRUSADE  score  for  in-hospital  major  bleeding
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IHMB)  and  determination  of  independent  predictors  of
HMB.
IHMB  was  defined  according  to  the  GUSTO  classification  as
ntracerebral  bleeding  or  bleeding  resulting  in  hemodynamic
ompromise  requiring  treatment.13 The  CRUSADE  score  was
alculated  from  eight  variables  (baseline  hematocrit,  esti-
ated  creatinine  clearance,  baseline  heart  rate,  baseline
ystolic  blood  pressure,  gender,  signs  of  heart  failure  on  pre-
entation,  prior  vascular  disease,  and  diabetes).  The  five
leeding  risk  categories  defined  by  the  CRUSADE  investiga-
ors  were  used:  very  low  risk  (score  ≤20),  low  risk  (21-30),
oderate  risk  (31-40),  high  risk  (41-50),  and  very  high  risk
>50).
tatistical  analysis
 descriptive  analysis  was  performed  to  characterize  the
tudy  sample.  Continuous  variables  are  presented  as  mean
 standard  deviation  and  categorical  variables  as  number
percentage).
The  predictive  ability  of  the  CRUSADE  score  in  our  pop-
lation  was  tested  using  the  area  under  the  curve  (AUC)  on
eceiver  operating  characteristic  analysis14 and  the  model’s
oodness  of  fit  was  assessed  by  the  Hosmer-Lemeshow
est,15 in  which  adequate  goodness  of  fit  is  indicated  by  a
on-significant  p  value.
Associations  between  categorical  variables  were  ana-
yzed  using  the  chi-square  test  and  continuous  variables
sing  the  Student’s  t  test.
Binary  logistic  regression  analysis  was  used  to  determine
redictors  of  IHMB.  A  p-value  of  <0.05  was  considered  to
ndicate  a  95%  significance  level.  IBM  SPSS  Statistics  (version
0.0)  was  used  for  the  statistical  analysis.
esults
opulation  characteristics
he  baseline  characteristics  of  the  study  population  are  pre-
ented  in  Table  1.
A total  of  2818  ACS  patients  were  included,  73.9%  male,
ean  age  66±13  years.  At  admission,  mean  hematocrit  was
1±5%,  mean  heart  rate  was  77±18  bpm,  mean  systolic
lood  pressure  was  139±30  mmHg,  mean  creatinine  clear-
nce  was  81±37  ml/min,  and  10.9%  presented  signs  of  heart
ailure.
The  most  frequent  diagnosis  at  admission  was  NSTEMI
48.4%),  followed  by  STEMI  (44.4%).  Coronary  angiography
as  performed  in  75.3%  of  patients  (91.5%  by  radial  access),
nd  58.3%  underwent  PCI.
With  regard  to  antithrombotic  therapy  during  hospitaliza-
ion,  96.8%  of  the  patients  received  aspirin,  73%  clopidogrel,
.8%  ticagrelor  and  47.9%  fondaparinux.
During  hospital  stay,  113  (4.0%)  patients  died  and  52
1.8%)  presented  IHMB.
iscriminatory  power  of  the  CRUSADE  scorehe  rate  of  IHMB  predicted  in  the  study  population  was  7.1%,
hile  the  observed  rate  was  1.8%,  a  statistically  significant
ifference  (p<0.001)  (Table  2).
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Table  1  Baseline  characteristics  of  the  study  population
(n=2818).
Demographic  data
Age,  years 66±13
Male  gender  73.9
Cardiovascular  risk  factors
Hypertension  67.7
Dyslipidemia  59.9
Smoking  31.5
Diabetes  28.6
Personal  history
Heart  failure 5.8
Coronary  angioplasty  17.8
CABG 5.6
MI 25.2
Vascular  diseasea 16.3
Bleeding  3.2
Baseline  clinical  and  laboratory  data
Signs  of  heart  failure 10.9
Heart  rate,  bpm 77±18
SBP,  mmHg 139±30
Hematocrit  41±5
Creatinine  clearance,  ml/minb 81±37
Type  of  ACS
STEMI  44.4
NSTEMI  48.4
MI of  undetermined  location  3.4
Unstable  angina  3.7
Coronary  angiography  75.3
Radial access  91.5
Femoral  access  8.5
PCI 58.3
Antithrombotic  therapy
Aspirin  96.8
Clopidogrel  73.0
Ticagrelor 2.8
GP IIb/IIIa  inhibitors 49.0
Fondaparinux  47.9
Enoxaparin  16.6
Warfarin 5.1
IHMB 1.8
In-hospital  mortality  4.0
ACS: acute coronary syndrome; CABG: coronary artery bypass
graft surgery; GP: glycoprotein; IHMB: in-hospital major
bleeding; MI: myocardial infarction; NSTEMI: non-ST-elevation
myocardial infarction; PCI: percutaneous coronary intervention;
SBP: systolic blood pressure; STEMI: ST-elevation myocardial
infarction. Data are presented as mean ± standard deviation
or as percentage.
a Defined as peripheral arterial disease or previous stroke.
b Estimated by the Cockcroft-Gault formula.
Table  2  In-hospital  major  bleeding  observed  in  the  study
population  and  predicted  by  the  CRUSADE  score.
Observed,
n  (%)
Predicted  by  the
CRUSADE  score,  %
p
IHMB  52  (1.8) 7.1  <0.001
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The  incidence  of  IHMB  in  the  different  categories  of  the
RUSADE  score  was  0.5%  in  the  very  low  risk  category  (rate
redicted  by  the  score  3.1%),  1.5%  in  the  low  risk  category
5.5%),  1.6%  in  the  moderate  risk  category  (8.6%),  5.5%  in  the
igh  risk  category  (11.9%),  and  4.4%  in  the  high  risk  category
19.5%)  (Table  3).
The  predictive  ability  of  the  CRUSADE  score  in  the  study
opulation  was  moderate,  with  an  AUC  of  0.73  (Figure  1).
redictors  of  in-hospital  major  bleeding
he  occurrence  of  IHMB  was  associated  with  the  fol-
owing  variables:  advanced  age  (p=0.01),  hypertension
p=0.029),  angina  (p=0.01),  previous  bleeding  (p<0.001),
OPD  (p=0.021),  cancer  (p<0.001),  higher  baseline  heart
ate  (p<0.001),  lower  hemoglobin  (p=0.005),  femoral  access
p<0.001),  and  lower  LVEF  at  discharge  (p<0.001).  IHMB  was
lso  associated  with  higher  in-hospital  mortality  (15.4%  vs.
.8%;  p<0.001)  (Table  4).
When  the  above  significant  associations  were  included
n  multivariate  analysis,  advanced  age  (p=0.027),  femoral
ccess  (p=0.004),  higher  heart  rate  (p=0.047)  and  medi-
ation  with  ticagrelor  during  hospital  stay  (p=0.027)  were
dentified  as  independent  predictors  of  IHMB  (Table  5).
iscussion
n  this  contemporary  population  of  patients  with  ACS,  the
RUSADE  score  overestimated  the  risk  of  IHMB.
n-hospital  major  bleeding
he  incidence  of  IHMB  in  the  literature  is  1-10%;  this  vari-
bility  is  due  to  various  factors  including  differences  in
atient  characteristics,  concomitant  therapy  and  definitions
f  bleeding.3
The  rate  of  IHMB  in  our  study  was  1.8%.  This  is  signif-
cantly  lower  than  that  predicted  by  the  CRUSADE  score
7.1%)  (p<0.001).  The  CRUSADE  score  overestimated  bleed-
ng  risk  in  all  risk  categories,  with  greater  differences  in
igher  risk  categories  (moderate,  high  and  very  high).
These  findings  may  be  explained  by  evidence  that  the
ate  of  IHMB  in  patients  with  ACS  has  decreased  over  time,
espite  the  use  of  more  aggressive  drug  therapies  and
nterventions.  Fox  et  al.  reported  a  significant  fall  in  bleed-
ng  rates  in  patients  with  ACS  between  2000  and  2007,
rom  2.6%  to  1.8%  (p<0.001).16 Factors  contributing  to  this
ecrease  include  improvements  in  cardiac  catheterization
echniques,  the  introduction  of  smaller  catheters,  the  use
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Table  3  In-hospital  major  bleeding  observed  in  the  study  population  and  predicted  by  the  CRUSADE  score  according  to  CRUSADE
risk categories.
Bleeding  risk  n=2615  Observed  IHMB,  n  (%)  IHMB  predicted  by  the  CRUSADE  score,  %
Very  low  (1-20)  931  5  (0.5)  3.1
Low (21-30)  681  10  (1.5)  5.5
Moderate (31-40)  509  8  (1.6)  8.6
High (41-50)  289  16  (5.5)  11.9
Very high  (>50)  205  9  (4.4)  19.5
IHMB: in-hospital major bleeding.
AUC 0.73
1-Specificity
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Figure  1  Receiver  operating  characteristic  curve  of  the  CRU-
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oSADE  score  for  predicting  in-hospital  major  bleeding  in  our
population.
of  radial  access,  better  selection  of  antithrombotic  therapy
and  changes  to  thresholds  for  red  blood  cell  transfusion.16
Patients  with  IHMB  have  a  worse  prognosis,  with  greater
risk  for  in-hospital  mortality.16,17 In  a  study  by  Spencer  et  al.
of  40  087  patients  with  MI,  IHMB  was  associated  with  greater
mortality  (21%  vs.  6%,  p<0.001).17 IHMB  was  also  associated
with  higher  mortality  in  our  study  (15.4%  vs.  3.8%,  p<0.001).
Measures  must  be  taken  to  reduce  the  negative  impact  of
IHMB  on  prognosis  in  ACS.  However,  several  risk  factors  for
bleeding  are  also  predictors  of  ischemic  events,  complicat-
ing  the  task  of  maximizing  anti-ischemic  effectiveness  while
minimizing  bleeding  risk.7,10
Discriminatory  power  of  the  CRUSADE  score
The  ability  of  the  CRUSADE  score  to  predict  IHMB  in  our
population  was  acceptable,  with  an  AUC  of  0.73.  However,
this  is  hardly  an  optimal  result.  In  a  cohort  of  4500  patients
with  ACS,  Abu-Assi  et  al.  assessed  the  performance  of  the
CRUSADE  score,  finding  a  c-statistic  of  0.80  for  predicting
major  bleeding  events,9 and  similarly,  Manzano-Fernández
et  al.  calculated  an  AUC  of  0.79  in  a  study  of  1587  patients
with  ACS.1 However,  other  studies  have  reported  lower  fig-
ures:  the  AUC  was  0.70  in  a  study  of  1976  patients  with
i
w
o
MCS  by  Ariza-Solé  et  al.,18 while  Amador  et  al.  found  an
UC  of  0.61  in  their  population  of  516  ACS  patients.19 The
RUSADE  score  has  been  shown  to  have  poor  predictive
bility,  with  AUC  values  below  0.70,  in  certain  subgroups,
ncluding  those  aged  over  75  years,  those  who  have  not
ndergone  coronary  angiography,  and  those  not  receiving
nticoagulant  therapy.9,20,21 Its  performance  was  actually
ather  modest  (AUC  0.68)  in  the  population  in  which  the
core  was  developed.7
There  is  thus  considerable  variability  in  the  discrimi-
atory  power  of  the  CRUSADE  score  in  ACS  patients.  This
ay  be  due  to  a range  of  factors  that  hinder  assessment  of
leeding  risk,  including  age,  comorbidities,  antithrombotic
herapy,  choice  of  strategy  (invasive  or  conservative),  and
ite  of  vascular  access  for  angiography.  There  is  a  need  for
 score  that  is  suitable  for  current  clinical  practice  and  that
an  provide  accurate,  individualized  and  simple  bleeding
isk  stratification  in  patients  with  ACS.
redictors  of  in-hospital  major  bleeding
he  independent  predictors  of  IHMB  identified  in  our  study
ere  advanced  age,  higher  heart  rate  on  admission,  femoral
ccess  and  medication  with  ticagrelor  during  hospital  stay.
As  pointed  out  above,  patients  with  ACS  are  a  hetero-
eneous  population,  which  means  that  different  predictors
f  major  bleeding  will  be  found  in  different  patient  popu-
ations.  A  study  by  Mehran  et  al.  in  17  421  patients  with
CS  identified  seven  predictors  of  bleeding,  including  female
ender,  advanced  age,  elevated  serum  creatinine,  white  cell
ount,  anemia  and  use  of  unfractionated  heparin  plus  a
P  IIb/IIIa  inhibitor.22 Moscucci  et  al.  determined  female
ender,  advanced  age,  renal  insufficiency  and  history  of
leeding  as  independent  predictors  of  bleeding  among
4  045  ACS  patients  in  the  GRACE  registry.23 As  well  as
ge,  female  gender  and  renal  insufficiency,  Nikolsky  et  al.
dentified  pre-existing  anemia,  administration  of  low  molec-
lar  weight  heparin  within  48  hours  pre-PCI,  and  use  of
ntra-aortic  balloon  pump  as  predictors  of  major  bleeding.24
lthough  there  are  differences  between  these  studies  in  the
ncidence  and  definition  of  bleeding,  age,  female  gender
nd  renal  failure  are  frequently  identified  variables.2,22,23 In
ur  study,  ticagrelor  use  was  a  predictor  of  IHMB,  although
t  should  be  borne  in  mind  that  only  2.8%  of  our  population
ere  taking  the  drug.  In  the  PLATO  trial,  compared  to  clopid-
grel,  treatment  with  ticagrelor  reduced  vascular  mortality,
I  and  stroke,  but  was  associated  with  a  higher  rate  of  bleed-
894  D.  Bento  et  al.
Table  4  Variables  associated  with  in-hospital  major  bleeding.
No  IHMB  (n=2766)  IHMB  (n=52)  p  OR  (95%  CI)
Age,  years 66±13 74±11  0.01  3.65  (2.05-6.92)a
Hypertension  67.4  82.0  0.029  2.31  (1.12-4.76)
Angina 39.0  56.9  0.01  2.13  (1.22-3.72)
Previous bleeding  2.9  20.0  <0.001  7.99  (3.87-16.50)
COPD 4.8  11.8  0.021  2.58  (1.08-6.15)
Cancer 4.2  15.7  <0.001  4.15  (1.91-9.02)
Heart rate,  bpm  76±18  88±27  <0.001  4.01  (3.15-8.03)b
Hemoglobin,  g/dl  13.8±1.8  13.1±2.2  0.005  2.90  (1.06-5.85)c
Femoral  access 8.0  35.1  <0.001  6.10  (3.39-10.97)
LVEF 57±13 49±12 <0.001 5.15  (3.01-8.57)d
Enoxaparin  16.3  32.7  0.002 2.49  (1.38-4.49)
Warfarin 5.0  11.5  0.034  2.48  (1.04-5.92)
Ticagrelor 2.7  9.1  0.028  3.81  (1.48-9.87)
Mortality 3.8  15.4  <0.001  4.61  (2.12-10.03)
CI: confidence interval; COPD: chronic obstructive pulmonary disease; IHMB: in-hospital major bleeding; LVEF: left ventricular ejection
fraction; OR: unadjusted odds ratio. Data are presented as mean ± standard deviation or as percentage.
a For each additional 5 years.
b For each additional 5 bpm.
c For each reduction of 0.5 g/dl.
d For each reduction of 5%.
Table  5  Predictors  of  in-hospital  major  bleeding.
p  OR  (95%  CI)
Age  0.027  4.89  (3.01-7.13)
Heart rate  0.047  3.95  (1.87-8.10)
Femoral  access  0.004  8.29  (5.01-10.18)
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iTicagrelor  0.027  4.92  (1.89-8.15)
CI: confidence interval; OR: adjusted odds ratio.
ng  not  related  to  coronary  artery  bypass  graft  surgery  (4.5%
s.  3.8%;  p=0.03).25
ascular  access  for  coronary  angiography
n  our  study,  91.5%  of  patients  underwent  angiography  via
adial  access,  a  higher  proportion  than  in  other  studies
ssessing  the  applicability  of  the  CRUSADE  score,  which
eported  rates  between  64%  and  83.1%.1,9,18,26 In  multivari-
te  analysis,  femoral  access  was  an  independent  predictor
f  IHMB  (p=0.004),  which  is  in  line  with  recent  clinical
vidence.27,28 However,  when  interpreting  this  result  it
hould  be  borne  in  mind  that  femoral  access  was  used  in
nly  8.5%  of  patients.
Periprocedural  major  bleeding  is  a  complication  that  can
ffect  patients  undergoing  PCI,  with  an  incidence  of  1.7-
.5%  in  recent  studies.29--31 Multiple  studies  have  shown  that
adial  access  is  associated  with  lower  rates  of  periprocedural
leeding  than  femoral  access.32--35
The  RIVAL  trial  reported  a  lower  rate  of  major  vas-
ular  complications  for  radial  access  in  patients  with
CS  (1.4%  vs.  3.7%;  p<0.0001).35 However,  results  for
ortality  were  inconsistent,  with  lower  mortality  in
atients  with  STEMI  but  not  in  those  with  non-ST-elevation
G
a
s
oCS  (NSTE-ACS).  In  the  MATRIX  trial,  radial  access  reduced
leeding  complications  and  overall  mortality  in  patients  with
CS  (STEMI  and  NSTEMI)  compared  to  femoral  access.27 In
he  European  guidelines  the  use  of  radial  access  is  a  class  I
ecommendation,  level  of  evidence  A.10
The  high  rate  of  radial  access  in  our  study  may  have  con-
ributed  to  the  low  rate  of  IHMB  in  our  population.  The  fact
hat  access  type  is  not  included  in  its  parameters  constitutes
 limitation  of  the  CRUSADE  score.
ondaparinux
egarding  anticoagulation,  fondaparinux  was  used  in  47.9%
f  our  population,  considerably  more  than  enoxaparin
16.6%).
In  the  OASIS-5  trial  in  patients  with  NSTE-ACS,  fon-
aparinux  significantly  reduced  major  bleeding  events
ompared  to  enoxaparin  (p<0.001).36 Fondaparinux  is  the
arenteral  anticoagulant  recommended  in  the  current
uidelines  for  NSTE-ACS  patients,  due  to  its  safety  and
fficacy  profile.10 Despite  this  recommendation,  rates  of
ondaparinux  use  in  other  series  are  lower  than  in  ours  (1.6-
4%).1,9,37
We  believe  that  the  use  of  this  anticoagulant  in  our  pop-
lation  may  also  have  contributed  to  the  low  rate  of  IHMB.
lycoprotein  IIb/IIIa  inhibitors  and  P2Y12 receptor
nhibitorsP  IIb/IIIa  inhibitors  were  used  in  49%  of  our  population,
 higher  rate  than  in  other  series  (5.7-40.2%).1,9,18,19,37 It
hould,  however,  be  noted  that  in  most  cases  this  consisted
nly  of  the  administration  of  a  bolus  of  eptifibatide  during
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coronary  angiography  and  that  the  drug  was  not  infused  after
angioplasty,  which  may  have  contributed  to  our  low  rate  of
periprocedural  bleeding  complications.
There  is  evidence  that  in  patients  with  NSTE-ACS
undergoing  PCI,  GP  IIb/IIIa  inhibitors  reduce  ischemic
events,  mainly  reinfarction,  although  they  also  increase
bleeding.6,38
Following  the  HORIZONS-AMI  trial,  which  showed  that
anticoagulation  with  bivalirudin  alone  was  superior  to
heparin  plus  GP  IIb/IIIa  inhibitors  in  patients  undergoing
primary  PCI,  with  significantly  reduced  30-day  rates  of
major  bleeding  and  mortality,39 use  of  GP  IIb/IIIa  inhibitors
declined.  The  current  European  guidelines  recommend  GP
IIb/IIIa  inhibitors  only  for  bailout  or  in  cases  of  thrombotic
complications  (class  IIa  recommendation,  level  of  evidence
C).10,40
By  contrast,  the  US  guidelines6 state  that  in  patients  with
NSTE-ACS  and  high-risk  features  not  adequately  pretreated
with  clopidogrel  or  ticagrelor,  it  is  useful  to  administer  a  GP
IIb/IIIa  inhibitor  (class  I  recommendation,  level  of  evidence
A),  and  in  NSTE-ACS  patients  treated  with  unfractionated
heparin  and  adequately  pretreated  with  clopidogrel,  it  is
reasonable  to  administer  a  GP  IIb/IIIa  inhibitor  (class  IIa
recommendation,  level  of  evidence  B).
It  should  be  noted  that  our  patients  preferably  received
a  P2Y12 receptor  inhibitor  during  or  after  angioplasty,  which
may  also  have  contributed  to  the  low  rate  of  major  bleeding.
Current  guidelines  recommend  pretreatment  with  a  P2Y12
receptor  inhibitor  for  patients  with  ACS.6,10,40 However,
questions  have  been  raised41,42 concerning  pretreatment  in
NSTE-ACS,  such  as  by  the  ACCOAST  trial,42 which  demon-
strated  that  pretreatment  with  prasugrel  did  not  reduce  the
rate  of  ischemic  events,  but  did  increase  the  rate  of  major
bleeding.
Clinical  implications
Antithrombotic  therapy,  which  is  an  essential  part  of  anti-
ischemic  therapy  in  ACS,  also  increases  bleeding  risk.
Patients  with  ACS  are  a  highly  heterogeneous  population  and
stratification  of  both  ischemic  and  bleeding  risk  is  needed
in  order  to  institute  appropriate  therapy  with  the  desired
efficacy  while  minimizing  undesired  effects.31 However,  in
the  last  ten  years  there  have  been  significant  changes  in  the
management  and  treatment  of  ACS  patients  that  may  have
altered  the  predictive  value  of  risk  scores.10 There  is  thus
a  need  to  develop  tools  to  stratify  bleeding  risk  that  aim  to
promote  strategies  that  reduce  bleeding  rates  and  thereby
improve  prognosis  in  these  patients.9
Limitations
This  was  a  single-center,  retrospective,  observational  study,
and  was  thus  subject  to  the  inherent  biases  of  such  studies.
The  low  rate  of  bleeding  events  may  have  influenced  the
results,  which  should  be  validated  in  a  larger  patient  cohort.
The  use  of  different  definitions  of  major  bleeding  is
another  limitation  of  our  study.  In  the  CRUSADE  trial,
major  bleeding  was  defined  as  intracranial  hemorrhage,
documented  retroperitoneal  bleed,  hematocrit  drop  ≥12%
(baseline  to  nadir),  any  red  blood  cell  transfusion  whenonary  syndrome?  895
aseline  hematocrit  ≥28%,  or  any  red  blood  cell  trans-
usion  when  baseline  hematocrit  <28%  with  witnessed
leed.  In  our  study  the  GUSTO  classification  was  used,
hich  defines  major  bleeding  as  intracerebral  bleeding  or
leeding  resulting  in  hemodynamic  compromise  requiring
reatment.13
onclusions
he  IHMB  rate  in  our  study  was  1.8%.  The  CRUSADE  score,
lthough  presenting  some  discriminatory  power,  significantly
verestimated  the  IHMB  rate,  especially  in  patients  at  higher
isk.  These  results  question  whether  the  CRUSADE  score
hould  continue  to  be  used  in  the  stratification  of  bleeding
isk  in  ACS  and  whether  specific  measures  should  be  taken
n  the  basis  of  the  score  result.
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